Klotho Neurosciences, Inc. (KLTO NASDAQ) stock market data APIs
$1.2588
-0.02(-1.6%)
as of July 14, 2025
Try our APIs with
free plan!
Klotho Neurosciences, Inc. Financial Data Overview
Price chart is built with
Anychart
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Prev. Close
1.2588
Open
1.2424
High
1.2981
Low
1.1324
52 wk Range
0.114-2.45
Market Cap
17 647 K
Shares Outstanding
21 264 K
EPS
-0.0812
Beta
0.024
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Klotho Neurosciences, Inc. data using free add-ons & libraries
Get Klotho Neurosciences, Inc. Fundamental Data
Klotho Neurosciences, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Klotho Neurosciences, Inc. News
New
Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its novel...
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical ...
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene
NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, includin...
Klotho Neurosciences terminates share exchange agreement with SkyBell
NEW YORK - Klotho Neurosciences, Inc. (NASDAQ:KLTO), a $50.37 million market cap biotech company whose shares have surged 243% over the past six months, announced on Wednesday that it has formally end...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
